Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure

American Journal of Hypertension

Volumn 29, Issue 5, 2016, Pages 549-552

  Liakos, Charalampos I ^a   Sanidas, Elias A ^a   Perrea, Despoina N ^b   Grassos, Charalampos A ^c   Chantziara, Vasiliki ^a   Viniou, Nora Athina ^a   Barbetseas, John D ^a   Papadopoulos, Dimitrios P ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c KAT HOSPITAL   (Greece)

Author keywords

apelin; high normal blood pressure; hypertension; visfatin

Indexed keywords

APELIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; APLN PROTEIN, HUMAN; BIOLOGICAL MARKER; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; SIGNAL PEPTIDE;

ADULT; APELIN BLOOD LEVEL; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY FUNCTION; MALE; MIDDLE AGED; NORMAL HUMAN; PRIORITY JOURNAL; SMOKING; VISFATIN BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; ENZYME LINKED IMMUNOSORBENT ASSAY; PREDICTIVE VALUE; REFERENCE VALUE; RISK ASSESSMENT; RISK FACTOR;

BIOMARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RISK ASSESSMENT; RISK FACTORS;

EID: 84965130925     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpv136     Document Type: Article

References (20)

1. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
2. Romacho T, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm 2013; 2013:946427.
3. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107:198-211.
4. Charles CJ. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovasc Hematol Agents Med Chem 2007; 5:1-10.
5. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001; 99:87-92.
6. Zhu P, Lin F, Huang F, Huang Q, Li Q, Gao Z, Chen F. Apelin and APLN single nucleotide polymorphisms and combined hypertension and central retinal artery stenosis in a Chinese population. Clin Exp Hypertens 2015; 37:280-287.
7. Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens 2011; 29:971-979.
8. Papadopoulos DP, Mourouzis I, Faselis C, Perrea D, Makris T, Tsioufis C, Papademetriou V. Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (Greenwich) 2013; 15:333-336.
9. Papadopoulos DP, Makris T, Perrea D, Zerva K, Tsioufis C, Faselis C, Papademetriou V. Apelin and relaxin plasma levels in young healthy offspring of patients with essential hypertension. J Clin Hypertens (Greenwich) 2014; 16:198-201.
10. Zhou Y, Wang Y, Qiao S. Apelin: a potential marker of coronary artery stenosis and atherosclerotic plaque stability in ACS patients. Int Heart J 2014; 55:204-212.
11. Akboga MK, Akyel A, Sahinarslan A, Demirtas CY, Yayla C, Boyaci B, Yalcin R. Relationship between plasma apelin level and coronary collateral circulation. Atherosclerosis 2014; 235:289-294.
12. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009; 71:202-207.
13. Kong Q, Xia M, Liang R, Li L, Cu X, Sun Z, Hu J. Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease. Singapore Med J 2014; 55:383-387.
14. Gunes F, Akbal E, Cakir E, Akyurek O, Altunbas M, Ozbek M. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. Intern Med 2012; 51:553-557.
15. Kocelak P, Olszanecka-Glinianowicz M, Owczarek A, Bożentowicz- Wikarek M, Brzozowska A, Mossakowska M, Zdrojewski T, Grodzicki T, Wiêcek A, Chudek J. Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly - results from the PolSenior substudy. J Am Soc Hypertens 2015; 9:1-8.
16. American Diabetes Association. Position Statement: Standards of Medical Care in Diabetes - 2012. Diabetes Care 2012; 35(Suppl 1):S11-S63.
17. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL; Task Force Members. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34:3035-3087.
18. Bełtowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit 2006; 12:RA112-RA119.
19. Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A, Castan-Laurell I, Tack I, Knibiehler B, Carpéné C, Audigier Y, Saulnier- Blache JS, Valet P. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146:1764-1771.
20. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426-430.